Rigel Pharmaceuticals, Inc.
NASDAQ:RIGLBiotechnology
-$0.62 today
- Market cap
- $800.84M
- Beta
- 1.18
- P/E (TTM)
- 1.7
- EPS (TTM)
- $19.78
Volume 0.24M
Average 0.36M
RIGL Total Liabilities
Everything the company owes to creditors and other parties.
Rigel Pharmaceuticals, Inc.NASDAQ: RIGL
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 33.5% from a year ago
Total liabilities stood at $104.71M at the end of Q1 FY2026, down 33.5% from a year earlier and down 14.3% from the prior quarter. Over 3 fiscal years it compounded at -6.2% a year.
Context
- Total liabilities amounted to 20.8% of total assets at the end of Q1 FY2026, down 68.7 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -33.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 122.11M USD
- Year-over-year change
- -24.0%
- 4-year CAGR
- -2.8%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 122.11M | -24.0% |
| FY2024 | 2024-12-31 | 160.69M | +10.2% |
| FY2023 | 2023-12-31 | 145.87M | -1.4% |
| FY2022 | 2022-12-31 | 147.9M | +8.0% |
| FY2021 | 2021-12-31 | 136.95M | — |
Total Liabilities vs competitors
How RIGL compares with its peers on the latest reported figures
- RIGL's Mar 2026 total liabilities of $104.71M is the 4th highest of the 10 companies compared; the peer median is $42.76M.
- Its year-over-year change of -33.5% is the lowest of 10, against a peer median of -6.6%.
- Total liabilities amounts to 20.8% of total assets for RIGL, versus a peer median of 26.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jul 2026 | $650.47M | +0.9% | +5.4% | 26.1% | |
| Aug 2026 | $226.99M | +51.1% | +9.7% | 19.0% | |
| Mar 2026 | $146.03M | -11.0% | +58.4% | 64.1% | |
| Mar 2026 | $104.71M | -33.5% | -6.2% | 20.8% | |
| Mar 2026 | $94.61M | -23.9% | -10.2% | 28.8% | |
| Dec 2025 | $42.76M | -6.6% | -48.5% | 124.2% | |
| Mar 2026 | $36.81M | +32.2% | +15.0% | 9.1% | |
| Mar 2026 | $26.98M | -17.2% | -8.4% | 15.1% | |
| Mar 2026 | $14.46M | +3.8% | +18.8% | 29.4% | |
| Mar 2026 | $6.56M | -20.4% | -42.3% | 16.2% | |
| Peer median (excluding RIGL) | $42.76M | -6.6% | +5.4% | 26.1% | |
Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 18.89M | 24.46M | 32.79M | 56.75M | 40.58M |
| Short-term Investments | 106.08M | 33.75M | 24.15M | 20.58M | 114.38M |
| Net Receivables | 15.47M | 40.32M | 30.55M | 41.62M | 51.76M |
| Inventory | 6.62M | 9.12M | 5.52M | 6M | 11.51M |
| Other Current Assets | 0 | 8.26M | 6.26M | 10.17M | 21.94M |
| Total Current Assets | 154.47M | 115.9M | 99.27M | 135.1M | 240.17M |
| Property, Plant & Equipment (Net) | 11.89M | 2.79M | 1.03M | 338K | 920K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 14.95M | 13.88M | 27.1M | 24.75M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 245.85M |
| Other Non-current Assets | 974K | 640K | 3.06M | 1.44M | 1.91M |
| Total Non-current Assets | 12.86M | 18.38M | 17.96M | 28.87M | 273.43M |
| Total Assets | 167.33M | 134.28M | 117.23M | 163.98M | 513.59M |
| Account Payables | 3.8M | 22.51M | 7.14M | 3.34M | 7.19M |
| Short-term Debt | 0 | 0 | 7.23M | 7.27M | 30.43M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 10.51M | 13.51M | 17.04M | 27.8M | 1.36M |
| Other Current Liabilities | 24.2M | 13.86M | 12.32M | 10.14M | 48.35M |
| Total Current Liabilities | 63.55M | 65.21M | 53.27M | 63.3M | 99.24M |
| Long-term Debt | 19.91M | 39.45M | 52.37M | 52.41M | 22.88M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 52.73M | 42.26M | 39.94M | 44.98M | 0 |
| Total Non-current Liabilities | 73.4M | 82.68M | 92.6M | 97.39M | 22.88M |
| Total Liabilities | 136.95M | 147.9M | 145.87M | 160.69M | 122.11M |
| Common Stock | 172K | 174K | 17K | 18K | 18K |
| Retained Earnings | (1.32B) | (1.38B) | (1.41B) | (1.39B) | (1.02B) |
| Accumulated OCI | (102K) | (153K) | 8K | 10K | 181K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 30.37M | (13.62M) | (28.64M) | 3.29M | 391.48M |
| Total Debt | 30.57M | 41.55M | 60.58M | 59.97M | 53.3M |
| Net Debt | 11.68M | 17.09M | 27.79M | 3.22M | 12.72M |
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
Intrinsic Alpha fair value
Locked
Current Price
$42.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.